Disclosed in the present disclosure are an azaheteroaryl compound, a pharmaceutically acceptable salt thereof, and a solvate thereof. The present disclosure also provides a method for preparing said compound, a composition containing said compound, and a use of said compound in the preparation of a drug for treating a disease or disorder related to the mechanism of action of an EED protein and/or a PRC2 protein complex. (Formula 1)

##STR00001##

A nitrogen-containing ring derivative regulator, a preparation method therefor and use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof as a G protein-coupled receptor regulator in the treatment or prevention of central nervous system diseases and/or mental diseases.

##STR00001##

The present invention relates to a compounds of general formula (I) inhibiting DDR1 and DDR2, particularly the invention relates to compounds that are benzylamine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of DDRs, in particular fibrosis.

The present invention relates to a compounds of general formula (I) inhibiting DDR1 and DDR2, particularly the invention relates to compounds that are benzylamine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of DDRs, in particular fibrosis.

The disclosure relates to organic electroluminescent elements, compounds for use in the elements, and devices using the elements, which include a compound represented by the following General Formula (1): ##STR00001##
where R.sup.1 to R.sup.3 and R.sup.6 to R.sup.8 each independently represents a hydrogen atom, which may be a deuterium atom, or a substituent with a Hammett substituent constant σ.sub.p value of −0.15 or more, R.sup.5, R.sup.9 and R.sup.10 each independently represents a hydrogen atom or a substituent, L.sup.1 represents a divalent linking group, DG.sup.1 represents a donor group, and n1 represents 1 or 2, and where R.sup.1 to R.sup.3, R.sup.5 to R.sup.10, L.sup.1, and DG.sup.1 are not bound to each other to form a ring.

The disclosure relates to organic electroluminescent elements, compounds for use in the elements, and devices using the elements, which include a compound represented by the following General Formula (1): ##STR00001##
where R.sup.1 to R.sup.3 and R.sup.6 to R.sup.8 each independently represents a hydrogen atom, which may be a deuterium atom, or a substituent with a Hammett substituent constant σ.sub.p value of −0.15 or more, R.sup.5, R.sup.9 and R.sup.10 each independently represents a hydrogen atom or a substituent, L.sup.1 represents a divalent linking group, DG.sup.1 represents a donor group, and n1 represents 1 or 2, and where R.sup.1 to R.sup.3, R.sup.5 to R.sup.10, L.sup.1, and DG.sup.1 are not bound to each other to form a ring.

Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.

Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.

The invention relates to pyrimidinone derivatives of the general Formula I, ##STR00001## or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

The invention relates to pyrimidinone derivatives of the general Formula I, ##STR00001## or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.